0001179110-16-024699.txt : 20160516
0001179110-16-024699.hdr.sgml : 20160516
20160516082542
ACCESSION NUMBER: 0001179110-16-024699
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160512
FILED AS OF DATE: 20160516
DATE AS OF CHANGE: 20160516
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OvaScience, Inc.
CENTRAL INDEX KEY: 0001544227
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 451472564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9 FOURTH AVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-500-2802
MAIL ADDRESS:
STREET 1: 9 FOURTH AVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dipp Michelle
CENTRAL INDEX KEY: 0001551614
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 161650790
MAIL ADDRESS:
STREET 1: C/O OVASCIENCE, INC.
STREET 2: 41 LINSKEY WAY, LEVEL B
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
edgar.xml
FORM 4 -
X0306
4
2016-05-12
0
0001544227
OvaScience, Inc.
OVAS
0001551614
Dipp Michelle
C/O OVASCIENCE, INC.
9 FOURTH AVE.
WALTHAM
MA
02451
1
1
0
0
Chief Executive Officer
Common Stock
2016-05-12
4
P
0
14200
6.72
A
455161
I
By Longwood Fund III LP
Common Stock
2016-05-12
4
P
0
5600
7.13
A
460761
I
By Longwood Fund III LP
Common Stock
2016-05-13
4
P
0
16295
7.06
A
477056
I
By Longwood Fund III LP
Common Stock
971921
D
This Form 4 reflects the purchase of an aggregate of 36,095 shares by the Longwood Fund III LP in the market. The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D. and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.99, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.00 to $7.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.62 to $7.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
/s/ William C. Hicks, Attorney-in-Fact
2016-05-16